Ikarian Capital’s Fulcrum Therapeutics FULC Stock Holding History
Bought
Maintained
Sold
Other funds holding FULC
Ikarian Capital's FULC Position: Q3 2026 in Review
Ikarian Capital reduced its Fulcrum Therapeutics (FULC) stake by 57% in Q3 2026, selling an estimated $2.25M and leaving 449,161 shares worth $1.66M. The position accounts for 0.17% of the portfolio, ranked #113.
Ikarian Capital first reported a position in FULC in Q4 2020 and has held it in 12 quarters since. The position peaked at $15.6M in Q4 2025. 151 funds tracked by Wall St. Rank hold FULC as of Q3 2026.
- Ikarian Capital held 449,161 shares of Fulcrum Therapeutics worth $1.66M as of Q3 2026.
- Ikarian Capital sold 600,000 Fulcrum Therapeutics shares in Q3 2026, an estimated $2.25M.
- Fulcrum Therapeutics made up 0.17% of Ikarian Capital's portfolio in Q3 2026, its #113 holding.
- Ikarian Capital first reported a position in Fulcrum Therapeutics in Q4 2020 and has held it in 12 quarters since.
- Ikarian Capital's Fulcrum Therapeutics position peaked at $15.6M in Q4 2025.
- 151 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2026.
Based on Ikarian Capital's 13F filing for Q3 2026, filed 16 Nov 2026.